AM630 is an inverse agonist at the human cannabinoid CB1 receptor

被引：46
|
作者：
Landsman, RS
Makriyannis, A
Deng, HF
Consroe, P
Roeske, WR
Yamamura, HI [1 ]
机构：
[1] Univ Arizona, Hlth Sci Ctr, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA
[2] Univ Arizona, Hlth Sci Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA
[3] Univ Arizona, Hlth Sci Ctr, Dept Biochem, Tucson, AZ 85724 USA
[4] Univ Arizona, Hlth Sci Ctr, Dept Med, Tucson, AZ 85724 USA
[5] Univ Arizona, Hlth Sci Ctr, Dept Psychiat, Tucson, AZ 85724 USA
[6] Univ Arizona, Hlth Sci Ctr, Program Neurosci, Tucson, AZ 85724 USA
[7] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
来源：
LIFE SCIENCES | 1998年 / 62卷 / 09期
关键词：
human cannabinoid CB1 receptor; inverse agonism; AM630; WIN 55,212-2; GTP gamma S; CHO cells; inverse agonist; negative intrinsic activity;
D O I：
10.1016/S0024-3205(97)01187-9
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The present investigation examines WIN 55,212-2 and AM630 at the cloned human cannabinoid CB1, receptor stably expressed in Chinese hamster ovary (CHO) cells. The effect of various concentrations of WIN 55,212-2 and AM630 on basal [S-35]GTP gamma S binding to cell membranes was determined. WIN 55,212-2 (100 mu M) stimulated basal [S-35]GTP gamma S binding 77.9% with an EC50 value of 0.36 mu M. Conversely, AM630 (100 mu M) inhibited basal [S-35]GTP gamma S binding by 20.9% with an EC50 value of 0.90 mu M These results show that WIN 55,212-2 is an agonist and AM630 is an inverse agonist in this system. (C) 1998 Elsevier Science Inc.
引用
收藏
页码：PL109 / PL113
页数：5
相关论文
共 50 条
  • [41] Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents
    Shearman, Lauren P.
    Stribling, D. Sloan
    Camacho, Ramon E.
    Rosko, Kimberly M.
    Wang, Junying
    Tong, Sharon
    Feng, Yue
    Marsh, Donald J.
    Yu, Hong
    Guan, Xiaoming
    Spann, Stephanie K.
    MacNeil, Douglas J.
    Fong, Tung M.
    Metzger, Joseph M.
    Goulet, Mark T.
    Hagmann, William K.
    Plummer, Christopher W.
    Finke, Paul E.
    Mills, Sander G.
    Shah, Shrenik K.
    Truong, Quang
    Van der Ploeg, L. H. T.
    Maclntyre, D. Euan
    Strack, Alison M.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 579 (1-3) : 215 - 224
  • [42] Homology model of the CB1 cannabinoid receptor:: Sites critical for nonclassical cannabinoid agonist interaction
    Shim, JY
    Welsh, WJ
    Howlett, AC
    BIOPOLYMERS, 2003, 71 (02) : 169 - 189
  • [43] Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia
    Jenko, Kimberly J.
    Hirvonen, Jussi
    Henter, Ioline D.
    Anderson, Kacey B.
    Zoghbi, Sami S.
    Hyde, Thomas M.
    Deep-Soboslay, Amy
    Innis, Robert B.
    Kleinman, Joel E.
    SCHIZOPHRENIA RESEARCH, 2012, 141 (2-3) : 185 - 188
  • [44] Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG-018
    Finlay, David B.
    Thuy Nguyen
    Gamage, Thomas F.
    Chen, Shuli
    Barrus, Daniel G.
    Patel, Purvi R.
    Thomas, Brian F.
    Wiley, Jenny L.
    Zhang, Yanan
    Glass, Michelle
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (01):
  • [45] The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: Evidence from postmortem human brain
    Erdozain, A. M.
    Diez-Alarcia, R.
    Meana, J. J.
    Callado, L. F.
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (02) : 260 - 268
  • [46] Toward the Design of Cannabinoid CB1 Receptor Inverse Agonists and Neutral Antagonists
    Reggio, Patricia H.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 585 - 600
  • [47] The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats
    Sink, K. S.
    Segovia, K. N.
    Collins, L. E.
    Markus, E. J.
    Vemuri, V. K.
    Makriyannis, A.
    Salamone, J. D.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2010, 95 (04) : 479 - 484
  • [48] Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist
    Amaya, Fumimasa
    Shimosato, Goshun
    Kawasaki, Yasuhiko
    Hashimoto, Satoru
    Tanaka, Yoshifumi
    Ji, Ru-Rong
    Tanaka, Masaki
    PAIN, 2006, 124 (1-2) : 175 - 183
  • [49] The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin mRNA by modulating food intake
    Thornton-Jones, ZD
    Vickers, SP
    Kennett, GA
    Benwell, KR
    Revell, DF
    Misra, A
    Sellwood, DM
    Clifton, PG
    BEHAVIOURAL PHARMACOLOGY, 2005, 16 : S22 - S23
  • [50] Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors
    Leggett, JD
    Aspley, S
    Beckett, SRG
    D'Antona, AM
    Kendall, DA
    Kendall, DA
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (02) : 253 - 262
12345